FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379341544> ?p ?o ?g. }

• W4379341544 endingPage "e18594" @default.
• W4379341544 startingPage "e18594" @default.
• W4379341544 abstract "e18594 Background: Ethically and scientifically clinical trials must be equally accessible. Unfortunately, racial and ethnic minorities, socioeconomically disadvantaged, elderly and rural populations continue to be underrepresented in all phases of cancer clinical trials due to multiple interrelated economic, cultural, social and medical barriers. Per U.S. 2010 census data about 57 million people (18-19% of the population) and 84% of the U.S. land mass qualify as rural. Examining the affect of geographic distance from trial sites and rural residency on patient enrollment in early phase cancer trials will aid in prioritizing how to address these barriers. Methods: We reviewed EMR data from 8/1/2016 to 8/1/2022 on all initial visits of consults and new patients with advanced cancer ( > 18 years of age) to a single institution phase 1 clinical trials unit. International patients and those without provided addresses were excluded. Bing geocode data for patient’s home zip codes was used in conjunction with the haversine distance formula to determine geographic distance to the cancer center. Rural-Urban Commuting Area codes, which classify U.S. 2010 census tracts based on zip codes using measures of population density, urbanization and daily commuting, were used to determine rural vs urban areas based on the Rural Health Research Center Categorization A and the Federal Office of Rural Health Policy definitions. Results: Among the 10,630 patients with diverse cancers referred to the phase 1 unit, 9182 patients (86.4%) were urban vs. 1448 (13.6%) rural. Patients from urban areas were more likely female 53.8% (4939) vs rural areas 49.2% (712). In terms of race, full data is provided in Table 1 with significantly less diversity in rural enrollment. Travel distance for study inclusion in urban vs rural patients was: 32.8% (3012) vs. 11.1% (161) < 100 miles, 37.0% (3396) vs. 53.9% (781) 100-499 miles, 19.7% (1813) vs. 26.2% (379) 500-1000 miles and 10.5% (961) vs. 8.8% (127) > 1000 miles. Overall, 75.6% (6944) patients from urban and 77.1% (1117) patients from rural areas consented to ≤ 1 study. Of those that consented 62.5% (4337) of urban patients and 64.0% (715) of rural patients enrolled in study. Conclusions: The largest Phase 1 cancer trial cohort of patients with advanced cancer with provided demographics and distance traveled for trial participation reveals disparities among U.S. rural vs. urban enrollment. Clearer understanding of these populations will allow for improved trial design and broad accrual. [Table: see text]" @default.
• W4379341544 created "2023-06-05" @default.
• W4379341544 creator A5002956398 @default.
• W4379341544 creator A5005436649 @default.
• W4379341544 creator A5008222365 @default.
• W4379341544 creator A5008786567 @default.
• W4379341544 creator A5026095888 @default.
• W4379341544 creator A5043675371 @default.
• W4379341544 creator A5044840107 @default.
• W4379341544 creator A5045197829 @default.
• W4379341544 creator A5058714044 @default.
• W4379341544 creator A5061237827 @default.
• W4379341544 creator A5068368047 @default.
• W4379341544 creator A5071750897 @default.
• W4379341544 creator A5073135717 @default.
• W4379341544 creator A5076426660 @default.
• W4379341544 creator A5092085248 @default.
• W4379341544 date "2023-06-01" @default.
• W4379341544 modified "2023-10-16" @default.
• W4379341544 title "Clinical trial deserts: US urban vs rural patient enrollment among patients with advanced cancer in phase 1 clinical trials at a major cancer center." @default.
• W4379341544 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e18594" @default.
• W4379341544 hasPublicationYear "2023" @default.
• W4379341544 type Work @default.
• W4379341544 citedByCount "0" @default.
• W4379341544 crossrefType "journal-article" @default.
• W4379341544 hasAuthorship W4379341544A5002956398 @default.
• W4379341544 hasAuthorship W4379341544A5005436649 @default.
• W4379341544 hasAuthorship W4379341544A5008222365 @default.
• W4379341544 hasAuthorship W4379341544A5008786567 @default.
• W4379341544 hasAuthorship W4379341544A5026095888 @default.
• W4379341544 hasAuthorship W4379341544A5043675371 @default.
• W4379341544 hasAuthorship W4379341544A5044840107 @default.
• W4379341544 hasAuthorship W4379341544A5045197829 @default.
• W4379341544 hasAuthorship W4379341544A5058714044 @default.
• W4379341544 hasAuthorship W4379341544A5061237827 @default.
• W4379341544 hasAuthorship W4379341544A5068368047 @default.
• W4379341544 hasAuthorship W4379341544A5071750897 @default.
• W4379341544 hasAuthorship W4379341544A5073135717 @default.
• W4379341544 hasAuthorship W4379341544A5076426660 @default.
• W4379341544 hasAuthorship W4379341544A5092085248 @default.
• W4379341544 hasConcept C121608353 @default.
• W4379341544 hasConcept C126322002 @default.
• W4379341544 hasConcept C129047720 @default.
• W4379341544 hasConcept C137403100 @default.
• W4379341544 hasConcept C138816342 @default.
• W4379341544 hasConcept C142724271 @default.
• W4379341544 hasConcept C144024400 @default.
• W4379341544 hasConcept C149923435 @default.
• W4379341544 hasConcept C159110408 @default.
• W4379341544 hasConcept C162324750 @default.
• W4379341544 hasConcept C19165224 @default.
• W4379341544 hasConcept C2250968 @default.
• W4379341544 hasConcept C2778527826 @default.
• W4379341544 hasConcept C2780623907 @default.
• W4379341544 hasConcept C2908647359 @default.
• W4379341544 hasConcept C50522688 @default.
• W4379341544 hasConcept C512399662 @default.
• W4379341544 hasConcept C52130261 @default.
• W4379341544 hasConcept C535046627 @default.
• W4379341544 hasConcept C71924100 @default.
• W4379341544 hasConcept C74909509 @default.
• W4379341544 hasConcept C99454951 @default.
• W4379341544 hasConceptScore W4379341544C121608353 @default.
• W4379341544 hasConceptScore W4379341544C126322002 @default.
• W4379341544 hasConceptScore W4379341544C129047720 @default.
• W4379341544 hasConceptScore W4379341544C137403100 @default.
• W4379341544 hasConceptScore W4379341544C138816342 @default.
• W4379341544 hasConceptScore W4379341544C142724271 @default.
• W4379341544 hasConceptScore W4379341544C144024400 @default.
• W4379341544 hasConceptScore W4379341544C149923435 @default.
• W4379341544 hasConceptScore W4379341544C159110408 @default.
• W4379341544 hasConceptScore W4379341544C162324750 @default.
• W4379341544 hasConceptScore W4379341544C19165224 @default.
• W4379341544 hasConceptScore W4379341544C2250968 @default.
• W4379341544 hasConceptScore W4379341544C2778527826 @default.
• W4379341544 hasConceptScore W4379341544C2780623907 @default.
• W4379341544 hasConceptScore W4379341544C2908647359 @default.
• W4379341544 hasConceptScore W4379341544C50522688 @default.
• W4379341544 hasConceptScore W4379341544C512399662 @default.
• W4379341544 hasConceptScore W4379341544C52130261 @default.
• W4379341544 hasConceptScore W4379341544C535046627 @default.
• W4379341544 hasConceptScore W4379341544C71924100 @default.
• W4379341544 hasConceptScore W4379341544C74909509 @default.
• W4379341544 hasConceptScore W4379341544C99454951 @default.
• W4379341544 hasIssue "16_suppl" @default.
• W4379341544 hasLocation W43793415441 @default.
• W4379341544 hasOpenAccess W4379341544 @default.
• W4379341544 hasPrimaryLocation W43793415441 @default.
• W4379341544 hasRelatedWork W1574911177 @default.
• W4379341544 hasRelatedWork W1995841756 @default.
• W4379341544 hasRelatedWork W2007307486 @default.
• W4379341544 hasRelatedWork W2165451421 @default.
• W4379341544 hasRelatedWork W2244690235 @default.
• W4379341544 hasRelatedWork W2390745362 @default.
• W4379341544 hasRelatedWork W2409484167 @default.
• W4379341544 hasRelatedWork W4302600660 @default.
• W4379341544 hasRelatedWork W2294912482 @default.
• W4379341544 hasRelatedWork W2725947673 @default.

• next